JAC Advance Access originally published online on August 26, 2005
Journal of Antimicrobial Chemotherapy 2005 56(4):769-772; doi:10.1093/jac/dki315
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003
1 Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 5th Floor, Basic Medical Sciences Building, 730 William Avenue, Winnipeg, Manitoba, R3E 0W3, Canada; 2 Clinical Microbiology, Health Sciences Centre, MS673-820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada
Received 21 June 2005; returned 25 July 2005; revised 5 August 2005; accepted 12 August 2005
* Corresponding author. Tel: +1-204-787-4684; Fax: +1-204-787-4699; E-mail: kris_schurek{at}yahoo.com
Objectives: To assess the prevalence of efflux and amino acid substitutions in ParC and GyrA in Canadian clinical isolates of fluoroquinolone-susceptible Streptococcus pneumoniae with levofloxacin MICs of 1 mg/L collected before the introduction of the respiratory fluoroquinolones (1995–1997) and after 7 years of use (2003).
Methods: Quinolone resistance determining regions of parC and gyrA were sequenced for 111 clinical isolates collected from 1995 to 1997 and 665 isolates collected in 2003. Efflux was assessed using a reserpine agar dilution method.
Results: No isolates exhibited efflux. No significant increase in isolates harbouring amino acid substitutions was observed over time (0.9% in 1995–1997 to 2.1% in 2003, P = 0.32). However, the proportion of isolates with a ciprofloxacin MIC = 2 mg/L and a levofloxacin MIC = 1 mg/L versus ciprofloxacin MIC = 1 mg/L and a levofloxacin MIC = 1 mg/L increased over time (3.6% to 6.5%, P = 0.0021).
Conclusions: No increase in prevalence of first-step parC mutations was observed among all fluoroquinolone-susceptible clinical isolates of S. pneumoniae with levofloxacin MICs of 1 mg/L after the introduction of the respiratory fluoroquinolones; however, fluoroquinolones appear to be selecting for isolates with elevated ciprofloxacin MICs.
Keywords: levofloxacin , mutations , efflux
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Hoshino, K. Inoue, Y. Murakami, Y. Kurosaka, K. Namba, Y. Kashimoto, S. Uoyama, R. Okumura, S. Higuchi, and T. Otani In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone Antimicrob. Agents Chemother., January 1, 2008; 52(1): 65 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ip, S. S. L. Chau, F. Chi, E. S. C. Cheuk, H. Ma, R. W. M. Lai, and P. K. Chan Longitudinally Tracking Fluoroquinolone Resistance and Its Determinants in Penicillin-Susceptible and -Nonsusceptible Streptococcus pneumoniae Isolates in Hong Kong, 2000 to 2005 Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2192 - 2194. [Abstract] [Full Text] [PDF]
|
|